<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855164</url>
  </required_header>
  <id_info>
    <org_study_id>CLJN452A2202</org_study_id>
    <secondary_id>2015-005215-33</secondary_id>
    <nct_id>NCT02855164</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)</brief_title>
  <acronym>FLIGHT-FXR</acronym>
  <official_title>A Randomized, Double-blind, Placebo Controlled, 3- Part, Adaptive Design, Multicenter Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH): FLIGHT-FXR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the effects of different doses of tropifexor (LJN452)
      with respect to safety, tolerability, and on markers of liver inflammation in patients with
      NASH
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2016</start_date>
  <completion_date type="Anticipated">September 23, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study was extended based on safety and efficacy results in Part A and available long-term toxicology coverage; Part C is added exploring 48 weeks of treatment at higher doses with paired biopsies in F2/3 NASH patients..</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event profile of different doses of tropifexor (LJN452) in patients with NASH</measure>
    <time_frame>12 weeks</time_frame>
    <description>Occurrence of Serious Adverse Event (SAE), Adverse Event (AE) resulting in treatment discontinuation and/or dose reductions, and AE of special interest, from baseline to week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Transaminase levels</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the dose relationship of tropifexor (LJN452) on markers of hepatic inflammation in NASH (ALT and AST) from baseline to Week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in % of fat in the liver assessed using MRI</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the dose-response relationship of tropifexor (LJN452) on liver fat content by changes in quantitative MRI determined fat from baseline to Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the effect of different doses of tropifexor (LJN452) on weight, after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in biomarker FGF19</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the dose-response relationship of tropifexor (LJN452) on FGF19 over time, a marker of FXR target engagement in the gut.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on on markers of liver fibrosis</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the dose-response relationship of tropifexor (LJN452) on markers of liver fibrosis commonly available such as Fibroscan®, enhanced liver fibrosis panel (ELF), and fibrosis biomarker test (originally known as Fibrotest®/ FibroSure®)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on gamma-glutamyl transferase (GGT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the dose-response relationship of tropifexor (LJN452) on GGT, a marker of cholestasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on fasting lipid profile</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the effect of tropifexor (LJN452) on fasting lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine Ctrough of LJN452</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the ctrough of tropifexor (LJN452)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itch based on a visual analog scale (VAS) rating scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>The score (distance from left) on the VAS will be recorded by the patient marking with a line. The distance marked will be converted to a score between 0 and 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BMI</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the effect of different doses of tropifexor (LJN452) on BMI, after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in waist-to-hip (WTH) ratio</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the effect of different doses of tropifexor (LJN452) on waist-to-hip (WTH) ratio after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in biomarker C4</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the dose-response relationship of LJN452 on C4, a marker of hepatic target engagement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine C2h of LJN452</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the pharmacokinetics (PK) of LJN452.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on above mentioned primary outcome measures in a subset of patients with history of biopsy data</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the dose-response relationship of tropifexor (LJN452) in a subset of patients with historical biopsy data (both overall and by subsets defined by fibrosis score and/or NAS score) on the following primary outcome measures: adverse event profile; change in transaminase levels; on liver fat content by changes in quantitative MRI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in baseline on fibrosis level , as assessed by liver biopsy</measure>
    <time_frame>48 weeks</time_frame>
    <description>To demonstrate the efficacy of tropifexor (LJN452) in patients with NASH and F2/F3 fibrosis, as assessed by improvement in liver biopsy from baseline to Week 48.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse event profile of different doses of tropifexor (LJN452) in patients with NASH</measure>
    <time_frame>48 weeks</time_frame>
    <description>SAE), Adverse Event (AE) resulting in treatment discontinuation and/or dose reductions, and AE of special interest, from baseline to Week 48.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in % of fat in the liver assessed using MRI</measure>
    <time_frame>48 weeks</time_frame>
    <description>To determine the dose-response relationship of tropifexor (LJN452) on liver fat content by changes in quantitative MRI determined fat from baseline to Week 48.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Transaminase levels</measure>
    <time_frame>48 weeks</time_frame>
    <description>To determine the dose relationship of tropifexor (LJN452) on markers of hepatic inflammation in NASH (ALT and AST) from baseline to Week 48.</description>
  </other_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">345</enrollment>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Part A - Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifexor (LJN452)- - dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifexor (LJN452)- - dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifezor (LJN452)- - dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifexor (LJN452)- - dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Arm E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Arm F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifexor (LJN452)- - dose to be determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Arm G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifexor (LJN452)- - dose to be determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Arm H</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C- Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifexor (LJN452)- dose 9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C- Arm J</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tropifexor (LJN452)- dose 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C- Arm K</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tropifexor (LJN452)</intervention_name>
    <description>Comparison of different doses of drug</description>
    <arm_group_label>Part A - Arm A</arm_group_label>
    <arm_group_label>Part A - Arm B</arm_group_label>
    <arm_group_label>Part A - Arm C</arm_group_label>
    <arm_group_label>Part A - Arm D</arm_group_label>
    <arm_group_label>Part B - Arm F</arm_group_label>
    <arm_group_label>Part B - Arm G</arm_group_label>
    <arm_group_label>Part C- Arm I</arm_group_label>
    <arm_group_label>Part C- Arm J</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Comparator</description>
    <arm_group_label>Part A - Arm E</arm_group_label>
    <arm_group_label>Part B - Arm H</arm_group_label>
    <arm_group_label>Part C- Arm K</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male/female patients, 18 years or older

          -  written informed consent

          -  Part A and B patients : presence of NASH by histological evidence (liver biopsy
             obtained 2 years or less prior to randomization) with fibrosis level of F1, F2 or F3
             (fibrosis in the absence of cirrhosis) and no diagnosis of chronic liver disease and
             elevated alanine aminotransferase (ALT) OR phenotypic diagnosis based on elevated ALT,
             BMI and diagnosis of Type 2 diabetes mellitus (DM)

          -  Part C patients: presence of NASH by histological evidence (liver biopsy obtained
             during the Screening period or 6 months or less prior to randomization) with fibrosis
             level of F2 or F3 and no diagnosis of chronic liver disease

        And ( All Parts):

          -  ALT ≥ 43 IU/L (males) or ≥ 28 IU/L (females)

          -  Liver fat equal to or higher than 10% by MRI

        Exclusion Criteria:

          -  previous exposure to OCA

          -  patients taking prohibited medications

          -  patients taking the following medicines UNLESS on a stable dose (within 25% of
             baseline dose) for at least 1 month before randomization: (for Part C patients, dose
             must be stable for at least 1 month prior to biopsy through Screening : anti- diabetic
             medications, insulin, beta-blockers, thiazide diuretics, fibrates, statins, niacin,
             ezetimibe, vitamin E (if doses &gt; 200 IU/day; doses &gt; 800 IU/day are prohibited),
             thyroid hormone, psychotropic medications, estrogen or estrogen containing birth
             control

          -  pregnant or nursing (lactating) women

          -  current or history of significant alcohol consumption for a period of more than 3
             consecutive months within 1 year prior to screening

          -  uncontrolled diabetes mellitus

          -  new use of GLP-1 agonists such as liraglutide, exenatide, lixisenatide, albiglutide or
             dulaglutide within 3 months of screening

          -  presence of cirrhosis

          -  hepatic decompensation or severe liver impairment

          -  previous diagnosis of other forms of chronic liver disease

          -  patients with contraindications to MRI imaging
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lonetree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>022215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208-2312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hatsukaichi-city</city>
        <state>Hiroshima</state>
        <zip>738 8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saga-city</city>
        <state>Saga</state>
        <zip>849-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izumo-city</city>
        <state>Shimane</state>
        <zip>693 8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97517</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>82606</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>83104</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaoshiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Keelung City</city>
        <zip>20401</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT02913105?term=NASH+novartis&amp;rank=2</url>
    <description>A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LJN452</keyword>
  <keyword>non-alcoholic steatohepatitis</keyword>
  <keyword>NASH</keyword>
  <keyword>phase 2</keyword>
  <keyword>adaptive design</keyword>
  <keyword>randomized</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

